Calcium
Active ingredient
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 6
- FDA reports (12 mo)
- 28,367
Overview
Plain-language summary, compiled from the cited regulatory records
Calcium is a mineral that is essential for life [1]. It plays a vital role in many bodily functions, including bone health, muscle contraction, and nerve signaling [1].
Calcium is approved for use in the INDICATION & USAGE SECTION [1]. This ingredient is available under various brand names [1].
In the past 12 months, there have been 28,367 adverse event reports associated with Calcium [2]. The most frequently reported adverse reactions include Fatigue, Off Label Use, Nausea, Diarrhoea, and Dyspnoea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | April 17, 2026 |
| US United States | FDA | 1 | January 23, 2024 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
4 products
Uses
Leucovorin (folinic acid) is the formyl derivative of tetrahydrofolic acid which is a metabolite and active form of folic acid. g. Methotrexate. g. methotrexate, to minimise systemic toxicity. c) The treatment of megaloblastic anaemias due to sprue, nutritional deficiency, pregnancy, infancy, liver disease and malabsorption syndrome.
How to take
USUnited States· FDA
1 product
Uses
INDICATION & USAGE SECTION take two capsules once, two times a day
How to take
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS .........................................................................................
5 ADVERSE REACTIONS........................................................................................................... 7 DRUG INTERACTIONS .........................................................................................................
10 DOSAGE AND ADMINISTRATION ..................................................................................... 13 OVERDOSAGE .......................................................................................................................
15 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 15 STORAGE AND STABILITY ................................................................................................. 19 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................
Sources & citations
- [1]MHRA (UK) · PL045150017 · revised January 2, 2026
- [2]FDA DailyMed · 11df7d66-7e85-d3… · revised January 23, 2024 [PDF]
- [3]Health Canada (DPD) · 02362414 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.